Reduced basal nitric oxide bioavailability and platelet activation in young spontaneously hypertensive rats

Biochemical Pharmacology

Volumn 67, Issue 12, 2004, Pages 2273-2279

  Schäfer, Andreas ^a,b   Widder, Julian ^a   Eigenthaler, Martin ^a   Ertl, Georg ^a   Bauersachs, Johann ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Endothelial factor; Endothelial function; Hypertension; Nitric oxide; Platelets

Indexed keywords

BINDING PROTEIN; CELL PROTEIN; FIBRINOGEN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; SERINE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

AGE DISTRIBUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME INHIBITION; FLOW CYTOMETRY; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT STRAIN; REDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; VASCULAR RING;

EID: 2442583364     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.02.034     Document Type: Article

References (49)

1. Preston R.A., Jy W., Jimenez J.J., Mauro L.M., Horstman L.L., Valle M., et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 41:2003;211-217
2. Blann A.D., Lip G.Y., Islim I.F., Beevers D.G. Platelet activation in hypertension. J. Hum. Hypertens. 11:1997;607-609
3. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., et al. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 348:2003;1104-1111
4. Schäfer A., Fraccarollo D., Hildemann S., Christ M., Eigenthaler M., Kobsar A., et al. Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and ACE inhibition: role of endothelial function and platelet VASP-phosphorylation. Thromb. Haemost. 89:2003;1024-1030
5. Gibbs C.R., Blann A.D., Watson R.D., Lip G.Y. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation. 103:2001;1746-1751
6. Tschoepe D., Roesen P., Schwippert B., Gries F.A. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Semin. Thromb. Hemost. 19:1993;122-128
7. Winocour P.D. Platelet abnormalities in diabetes mellitus. Diabetes. 41(Suppl. 2):1992;26-31
8. Targonski P.V., Bonetti P.O., Pumper G.M., Higano S.T., Holmes D.R. Jr., Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation. 107:2003;2805-2809
9. Yamazaki M., Uchiyama S., Iwata M. Measurement of platelet fibrinogen binding and P-selectin expression by flow cytometry in patients with cerebral infarction. Thromb. Res. 104:2001;197-205
10. Corseaux D., Ollivier V., Fontaine V., Huisse M.G., Philippe M., Louedec L., et al. Hemostasis imbalance in experimental hypertension. Mol. Med. 8:2002;169-178
11. Eigenthaler M., Nolte C., Halbruegge M., Walter U. Concentration and regulation of cyclic nucleotides. Eur. J. Biochem. 205:1992;471-481
12. Horstrup K., Jablonka B., Honig-Liedl P., Just M., Kochsiek K., Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur. J. Biochem. 225:1994;21-27
13. Aszódi A., Pfeifer A., Ahmad M., Glauner M., Zhou X.-H., Ny L., et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 18:1999;37-48
14. Hauser W., Knobeloch K.P., Eigenthaler M., Gambaryan S., Krenn V., Geiger J., et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96:1999;8120-8125
15. Massberg S., Grüner S., Konrad I., Garcia Arguinzonis M.I., Eigenthaler M., Hemler K., et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood. 103:2003;136-142
16. Oelze M., Mollnau H., Hoffmann N., Warnholtz A., Bodenschatz M., Smolenski A., et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ. Res. 87:2000;999-1005
17. 2+-independent activation of the endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 96:1999;1123-1128
18. Schwarz U.R., Geiger J., Walter U., Eigenthaler M. Flow cytometry analysis of intracellular VASP-phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets. Thromb. Haemost. 82:1999;1145-1152
19. Smolenski A., Bachmann C., Reinhard K., Honig-Liedl P., Jarchau T., Hoschuetzky H., et al. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J. Biol. Chem. 273:1998;20029-20035
20. Schäfer A., Vollkommer T., Burkhardt M., Bauersachs J., Münzel T., Walter U., et al. Endothelium-dependent and -independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. Biochem. Pharmacol. 65:2003;397-405
21. Schäfer A., Schulz C., Eigenthaler M., Fraccarollo D., Kobsar A., Gawaz M., et al. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood. 103:2004;407-412
22. Tarozzo G., Campanella M., Ghiani M., Bulfone A., Beltramo M. Expression of fractalkine and its receptor, CX3CR1, in response to ischemia-reperfusion brain injury in the rat. Eur. J. Neurosci. 15:2002;1663-1668
23. Umehara H., Bloom E., Okazaki T., Domae N., Imai T. Fractalkine and vascular injury. Trends Immunol. 22:2001;602-607
24. Fleming I., Busse R. NO: the primary EDRF. J. Mol. Cell Cardiol. 31:1999;5-14
25. Dowell F.J., Martin W., Dominiczak A.F., Hamilton C.A. Decreased basal despite enhanced agonist-stimulated effects of nitric oxide in 12-week-old stroke-prone spontaneously hypertensive rat. Eur. J. Pharmacol. 379:1999;175-182
26. Wirth K.J., Linz W., Wiemer G., Scholkens B.A. Differences in acetylcholine- and bradykinin-induced vasorelaxation of the mesenteric vascular bed in spontaneously hypertensive rats of different ages. Naunyn Schmiedebergs Arch. Pharmacol. 354:1996;38-43
27. Safar M., Chamiot-Clerc P., Dagher G., Renaud J.F. Pulse pressure, endothelium function, and arterial stiffness in spontaneously hypertensive rats. Hypertension. 38:2001;1416-1421
28. Chamiot-Clerc P., Colle M.H., Legrand M., Sassard J., Safar M.E., Renaud J.F. Evidence for a common defect associated with pressure in the aorta of two hypertensive rat strains. Clin. Exp. Pharmacol. Physiol. 26:1999;883-888
29. Nava E., Luscher T.F. Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. J. Hypertens. Suppl. 13:1995;S39-S48
30. Harbeck B., Huttelmaier S., Schluter K., Jockusch B.M., Illenberger S. Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. J. Biol. Chem. 275:2000;30817-30825
31. Schwarz U.R., Walter U., Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem. Pharmacol. 62:2001;1153-1161
32. Massberg S., Sausbier M., Klatt P., Bauer M., Pfeifer A., Siess W., et al. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′, 5′-monophosphate kinase I. J. Exp. Med. 189:1999;1255-1264
33. Jimenez A.M., Monton M., Garcia R., Nunez A., Gomez J., Rico L., et al. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. J. Cardiovasc. Pharmacol. 37:2001;406-412
34. Keh D., Thieme A., Kürer I., Falke K.J., Gerlach H. Inactivation of platelet glycoprotein IIb/IIIa receptor by nitric oxide donor 3-morpholino-sydnonimine. Blood Coagul. Fibrinolysis. 14:2003;327-334
35. Zhang L., Zhang Z.G., Zhang R., Morris D., Lu M., Coller B.S., et al. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke. Circulation. 107:2003;2837-2843
36. Massberg S., Brand K., Gruner S., Page S., Muller E., Muller I., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med. 196:2002;887-896
37. Gawaz M., Brand K., Dickfeld T., Pogatsa-Murray G., Page S., Bogner C., et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis. 148:2000;75-85
38. Abi-Younes S., Sauty A., Mach F., Sukhova G.K., Libby P., Luster A.D. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ. Res. 86:2000;131-138
39. Gear A.R., Suttitanamongkol S., Viisoreanu D., Polanowska-Grabowska R.K., Raha S., Camerini D. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC TARC and SDF-1 to stimulate platelet function. Blood. 97:2001;937-945
40. Combadiere C., Potteaux S., Gao J.L., Esposito B., Casanova S., Lee E.J., et al. Decreased atherosclerotic lesion formation in CX3CR1/Apolipoprotein E double knockout mice. Circulation. 107:2003;1009-1016
41. Lesnik P., Haskell C.A., Charo I.F. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111:2003;333-340
42. Soriano S.G., Amaravadi L.S., Wang Y.F., Zhou H., Yu G.X., Tonra J.R. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J. Neuroimmunol. 125:2002;59-65
43. Kunapuli S., Dorsam R.T., Kim S., Quinton T.M. Platelet purinergic receptors. Curr. Opin. Pharmacol. 3:2003;175-180
44. Inwald D.P., McDowall A., Peters M.J., Callard R.E., Klein N.J. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ. Res. 92:2003;1041-1048
45. Furie B., Furie B.C., Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion signaling and cell adhesion. Thromb. Haemost. 86:2001;214-221
46. Li N., Hu H., Lindqvist M., Wikstrom-Jonsson E., Goodall A.H., Hjemdahl P. Platelet-leukocyte cross talk in whole blood. Arterioscler. Thromb. Vasc. Biol. 20:2000;2702-2708
47. Andre P., Prasad K.S., Denis C.V., He M., Papalia J.M., Hynes R.O., et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat. Med. 8:2002;247-252
48. Lominadze D., Joshua I.G., Schuschke D.A. In vivo platelet thrombus formation in microvessels of spontaneously hypertensive rats. Am. J. Hypertension. 10:1997;1140-1146
49. Huzoor A., Kundu N., Kornhauser R. Normal thrombin binding leads to greater fibrinogen binding and increased platelet aggregation in spontaneously hypertensive rats. Life Sci. 53:1993;1967-1974